(Press-News.org) WASHINGTON -- A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive Cancer Center researchers conducting the study in cancer patients whose tumors have resisted multiple treatments say the combination demonstrates "promising evidence" of disease control and should be studied in a phase II trial. Their clinical findings and additional data from the study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1 through 5, 2012.
Temsirolimus is an mTOR inhibitor, meaning it stops mTOR from doing its job inside a cell. mTOR controls parts of a cell's machinery, including the production of proteins, and it is essential for cancer cell growth. However, researchers know it's not enough to stop one cellular mechanism in the vast majority of cancers. They hypothesize that by adding a chemotherapy, capecitabine, to temsirolimus, the combination will overwhelm the cancer cells and cause them to die.
Thirty-two patients with advanced cancers volunteered to participate in the phase I study of temsirolimus and capecitabine. The men and women had received an average of four previous types of treatments. The study was designed to examine the safety of various combination doses among the patients. Side effects were assessed in 30 patients.
The most common adverse events were mucositis (inflammation and ulceration of the mucous membranes lining the digestive tract), and hypophosphatemia (low level of phosphorus in the blood causing bone pain, confusion and muscle weakness). The most common serious adverse events were fatigue (4), diarrhea (2) and hypophosphatemia (2). For 16 of 30 patients, the dose of capecitabine was lowered to help alleviate side effects.
Of the 25 patients evaluable for the effectiveness of the combination, there were no partial responses or complete responses observed, but 14 patients had stable disease (no growth) – some with stable disease for more than six months. The median time to progression was three months with a median overall survival of seven months.
"We're not surprised by the safety profile of this combination," says the principal investigator, Michael Pishvaian, M.D., Ph.D., a gastrointestinal cancer specialist at Georgetown Lombardi. "While phase I studies are not designed to measure the tumor's response to a drug or combination of drugs, it is encouraging when we see some clinical benefit. Looking ahead, I anticipate this combination will be studied in phase II trial for colon cancer patients who have exhausted all options for treatments."
INFORMATION:
In addition to Pishvaian, other authors include Hongkun Wang, Ph.D., Rose Hardesty, RN John Deeken, M.D., A. Ruth He, M.D., Ph.D., Deepa Subramaniam, M.D., Tingting Zhuang, M.S., Damian L. McCarthy, B.S. Heather Melville, B.S. Chris Albanese, Ph.D., John L Marshall, M.D., and Jimmy Hwang, M.D.
Pishvaian reports no personal financial interests related to the study. Marshall occasionally serves as a paid consultant and scientific speaker on behalf of Roche Pharmaceuticals, the manufacturer of capecitabine. Hwang occasionally serves as a paid consultant for Genentech, a member of the Roche group.
This work was funded by Pfizer, Inc., the maker of temsirolimus.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and MedStar Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.
END
VIDEO:
This is a video showing and discussing results published in Nature from the BrainGate2 pilot clinical trial.
Click here for more information.
[Providence, R.I.] -- On April 12, 2011, nearly fifteen years after she became paralyzed and unable to speak, a woman controlled a robotic arm by thinking about moving her arm and hand to lift a bottle of coffee to her mouth and take a drink. That achievement is one of the advances in brain-computer interfaces restorative neurotechnology ...
Fotobabble, a leader in social media marketing solutions, announced the release of Fotobabble for Websites today, a new application that for the first time lets an organization run photo and audio-driven campaigns and promotions directly from any website. With Fotobabble for Websites brands and businesses can increase web traffic and audience engagement through the visual impact of photos, the emotion of voice and the power of social media.
Everloop.com, the leading online social site for kids and tweens, selected Fotobabble for Websites to power its INSPIRE contest ...
In an ongoing clinical trial, a paralyzed woman was able to reach for and sip from a drink on her own – for the first time in nearly 15 years – by using her thoughts to direct a robotic arm. The trial, funded in part by the National Institutes of Health, is evaluating the safety and feasibility of an investigational device called the BrainGate neural interface system. This is a type of brain-computer interface (BCI) intended to put robotics and other assistive technology under the brain's control.
A report published today in Nature describes how two individuals – both ...
Centaurus A, also known as NGC 5128 [1], is a peculiar massive elliptical galaxy with a supermassive black hole at its heart. It lies about 12 million light-years away in the southern constellation of Centaurus (The Centaur) and has the distinction of being the most prominent radio galaxy in the sky. Astronomers think that the bright nucleus, strong radio emission and jet features of Centaurus A are produced by a central black hole with a mass of about 100 million times that of the Sun. Matter from the dense central parts of the galaxy releases vast amounts of energy as ...
RIVERSIDE, Calif. — Black carbon aerosols and tropospheric ozone, both manmade pollutants emitted predominantly in the Northern Hemisphere's low- to mid-latitudes, are most likely pushing the boundary of the tropics further poleward in that hemisphere, new research by a team of scientists shows.
While stratospheric ozone depletion has already been shown to be the primary driver of the expansion of the tropics in the Southern Hemisphere, the researchers are the first to report that black carbon and tropospheric ozone are the most likely primary drivers of the tropical ...
In a study published today in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.
The team examined all the genes in the genomes of 100 cases of breast cancer. The mutated cancer-causing genes were different in different cancer samples, indicating that breast cancer is genetically very diverse. Understanding the consequences of this diversity will be important in progressing towards more rational treatment.
Changes to DNA lie behind all cases of cancer. ...
SEATTLE – A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease. The results of the study, led by Hutchinson Center computational biologist Harlan Robins, Ph.D., are reported in the May 16 issue of Science Translational Medicine.
"The ability to predict disease ...
While the mobile community continues to grow, Dr. Hahn, dentist in Kentwood, MI, is happy to offer an advanced mobile website to better meet the needs of patients who are constantly on the go. Today, in a technologically advanced society, more and more people are utilizing their smart phones and tablet devices for their daily needs. From ordering food to looking up important information, patients use their smart phones and tablet devices on a daily basis.
By offering a mobile website, Dr. Hahn, dentist in Kentwood, enhances his patients' ability to receive important ...
Common variants of the ApoE gene are strongly associated with the risk of developing late-onset Alzheimer's disease, but the gene's role in the disease has been unclear. Now, researchers funded by the National Institutes of Health have found that in mice, having the most risky variant of ApoE damages the blood vessels that feed the brain.
The researchers found that the high-risk variant, ApoE4, triggers an inflammatory reaction that weakens the blood-brain barrier, a network of cells and other components that lines brain's brain vessels. Normally, this barrier allows ...
Dr. Greg Herzler, Saginaw Township dentist, appreciates his patients' feedback about his practice. By leaving reviews, patients help Dr. Herzler to improve his practice to better serve his patients. Patients can visit the practice's website for instant access to available links to leave their feedback on the review site of their choice.
"I always look forward to hearing from my patients about their experience with my office. By leaving reviews, my patients allow me to constantly improve my practice and the way we serve our patients. I hope to continue to provide ...
